ES2111352T3 - Uso de diester fosfato para el tratamiento de enfermedades retinianas. - Google Patents

Uso de diester fosfato para el tratamiento de enfermedades retinianas.

Info

Publication number
ES2111352T3
ES2111352T3 ES95106990T ES95106990T ES2111352T3 ES 2111352 T3 ES2111352 T3 ES 2111352T3 ES 95106990 T ES95106990 T ES 95106990T ES 95106990 T ES95106990 T ES 95106990T ES 2111352 T3 ES2111352 T3 ES 2111352T3
Authority
ES
Spain
Prior art keywords
treatment
compound
retinal diseases
diester phosphate
prophylaxis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95106990T
Other languages
English (en)
Inventor
Hiroshi Kuriyama
Hiroaki Naka
Mitsunori Waki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2111352T3 publication Critical patent/ES2111352T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PRESENTA UNA COMPOSICION FARMACEUTICA PARA LA PROFILAXIS Y TRATAMIENTO DE UNA ENFERMEDAD RETINAL EN UN HUMANO QUE COMPRENDE (A) UN COMPUESTO DE FORMULA (I) DONDE R{SUP,1} Y R{SUP,2} INDEPENDIENTEMENTE UNO DE OTRO REPRESENTAN HIDROGENO O UN GRUPO METILO, O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES, Y (B) UN VEHICULO FARMACOLOGICAMENTE ACEPTABLE PARA ESTE. TAMBIEN SE PRESENTAN UN METODO PARA LA PROFILAXIS Y EL TRATAMIENTO DE UNA ENFERMEDAD RETINAL QUE CONSISTE EN ADMINISTRAR TAL COMPUESTO Y UN USO DE TAL COMPUESTO PARA PREPARAR UNA COMPOSICION FARMACEUTICA PARA EL MISMO PROPOSITO.
ES95106990T 1994-05-10 1995-05-09 Uso de diester fosfato para el tratamiento de enfermedades retinianas. Expired - Lifetime ES2111352T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP09593994A JP3396953B2 (ja) 1994-05-10 1994-05-10 網膜疾患予防・治療剤

Publications (1)

Publication Number Publication Date
ES2111352T3 true ES2111352T3 (es) 1998-03-01

Family

ID=14151246

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95106990T Expired - Lifetime ES2111352T3 (es) 1994-05-10 1995-05-09 Uso de diester fosfato para el tratamiento de enfermedades retinianas.

Country Status (9)

Country Link
US (1) US6069139A (es)
EP (1) EP0681840B1 (es)
JP (1) JP3396953B2 (es)
KR (1) KR950031087A (es)
AT (1) ATE161725T1 (es)
CA (1) CA2147587A1 (es)
DE (1) DE69501359T2 (es)
ES (1) ES2111352T3 (es)
TW (1) TW397685B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6986740B2 (en) * 1998-11-02 2006-01-17 Xantech Pharmaceuticals, Inc. Ultrasound contrast using halogenated xanthenes
AR030346A1 (es) 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
MXPA04000654A (es) 2001-07-27 2004-03-19 Vital Health Sciences Pty Ltd Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US20030187072A1 (en) * 2003-02-14 2003-10-02 Kapin Michael A. Method of treating angiogenesis-related disorders
RU2477136C2 (ru) 2004-03-03 2013-03-10 Вайтал Хэлф Сайнсис Пти Лтд Алкалоидные составы
RU2428973C2 (ru) * 2005-03-03 2011-09-20 Вайтал Хэлф Сайнсис Пти Лтд Составы, обладающие липидопонижающими свойствами
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA2794734C (en) 2010-03-30 2017-12-12 Phosphagenics Limited Transdermal delivery patch
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2854631B2 (ja) * 1989-11-21 1999-02-03 千寿製薬株式会社 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤

Also Published As

Publication number Publication date
TW397685B (en) 2000-07-11
ATE161725T1 (de) 1998-01-15
EP0681840A1 (en) 1995-11-15
KR950031087A (ko) 1995-12-18
JP3396953B2 (ja) 2003-04-14
CA2147587A1 (en) 1995-11-11
JPH07304676A (ja) 1995-11-21
US6069139A (en) 2000-05-30
EP0681840B1 (en) 1998-01-07
DE69501359D1 (de) 1998-02-12
DE69501359T2 (de) 1998-08-20

Similar Documents

Publication Publication Date Title
TR199801642T2 (xx) Tedavide faydal� olan karbamik asitlerin azabisiklik esterleri.
ES2071725T3 (es) Diesteres fosfato de acido ascorbico y tocoferilo para la inhibicion de la reaccion de maillard.
AR007828A1 (es) Compuestos derivados de piridilpirrol, procedimiento de preparacion y composiciones farmaceuticas conteniendo los mismos
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
HU9600834D0 (en) Quinazoline derivatives
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
AR008853A1 (es) Nuevos compuestos farmaceuticamente activos, su uso en la fabricacion de medicamentos, metodo de tratamiento, composicion farmaceutica, compuestosintermediarios y proceso para la fabricacion de dichos compuestos
ES2108717T3 (es) Derivados de la tetrahidropirrolo(1,2-a)pirazina-4-espiro-3'-pirrolidina, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
ATE89547T1 (de) Dopamin-vorlaeufer.
SE9702564D0 (sv) New compounds
DE69429591D1 (de) Therapeutisch wirksame Verbindungen
ES2163425T3 (es) Uso de raloxifeno y de sus analogos para la fabricacion de un medicamento para el tratamiento de la ateroesclerosis y la enfermedad cardiaca isquemica.
DE69501359D1 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
ES2051834T3 (es) El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad.
ES2107279T3 (es) Diesteres de fosfato para el tratamiento de enfermedades proliferativas de la epidermis.
BR9611276A (pt) Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto
ATE141605T1 (de) Thienotriazoldiazepinverbindungen und deren pharmazeutische anwendungen
DE68919378D1 (de) Thienotriazolodiazepine und ihre pharmazeutische Verwendung.
UA41329C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, похідні 3-фенілсульфоніл-3,7-діазабіцикло[3,3,1]нонану та лікарський засіб для лікування аритмії
ATE81130T1 (de) 4,5,6,7-tetrahydroisothiazolo (4,5-c)pyridinderivate und isomere.
NO950177D0 (no) Farmakologisk aktive erivater
NZ503027A (en) Use of rifamycin derivative for treating mastitis in a domestic animal
TR199900013T2 (xx) Yeni bile�ikler.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 681840

Country of ref document: ES